

Obituary of Professor Christophe Mariette

Journal:	<i>Diseases of the Esophagus</i>
Manuscript ID	Draft
Manuscript type:	Editorial
Date Submitted by the Author:	n/a
Complete List of Authors:	Piessen, Guillaume; Hopital Claude Huriez, Digestive and Oncological Surgery Triboulet, Jean-Pierre; Hopital Claude Huriez, Digestive and Oncological Surgery Schneider, Paul; Hirslanden Medical Center Nilsson , Magnus; Karolinska University Hospital, Gastrocentrum Siersema, Peter; Radboud University Nijmegen Medical Centre
Keywords:	esophageal and gastric cancer, Esophageal and gastric surgery, Esophageal diseases

Obituary of Professor Christophe Mariette

Guillaume Piessen¹, Jean-Pierre Triboulet¹, Paul M Schneider², Magnus Nilsson³ & Peter D
Siersema³

Affiliation:

1. Univ. Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, F-59000 Lille, France
2. Surgical Center Zurich for Visceral, Thoracic and Specialized Tumor Surgery, Hirslanden Medical Center, Zurich, Switzerland
3. European Society of Esophageal Disease, President & Secretary

1
2
3 It is with great sadness that we announce the death of Professor Christophe Mariette.
4

5 On Wednesday morning, July 19th 2017, the Claude Huriez University Hospital gradually
6
7 entered a state of somber astonishment. The news had spread over night; people already
8
9 informed arrive at their posts, silent and shocked. The staff of his department was informed
10
11 by his mentor, Professor Jean Pierre Triboulet; Christophe Mariette suddenly passed away on
12
13 July 18th at the age of 47.
14

15
16 Professor Mariette was the model of the modern surgeon, researcher and a worldwide
17
18 reference on upper gastro-intestinal surgery. With brilliant spirit and sharp intelligence, he
19
20 conceived and carried out several inspiring projects together with fellow surgeons and
21
22 oncologists. His hard work, scientific rigor and charismatic personality will stay in memory
23
24 for all who knew him.
25
26

27 Born on November 16th 1969, Christophe studied medicine at the Necker Faculty of
28
29 Medicine in Paris from 1987 to 1994 and was then appointed resident at the Lille University
30
31 Hospital from 1994 to 2001. During his residency, he met Professor Jean-Pierre Triboulet
32
33 who became his mentor. They developed a close collaboration and built a department
34
35 dedicated to oncological, and more specifically to esophago-gastric surgery. Appointed Senior
36
37 Resident in 2001, he conducted a PhD thesis dedicated to carcinogenesis of esophageal
38
39 adenocarcinoma, and obtained his PhD title in 2004. He then became Professor at the
40
41 University of Lille in 2006 and was appointed Head of the Department of Digestive and
42
43 Oncological Surgery in 2012 after the retirement of his mentor, Professor Triboulet. In
44
45 clinical research just as in translational research and in everyday practice, the patient
46
47 remained at the center of his concerns.
48
49
50

51 On a regional level, Professor Mariette became the Coordinator of the “Integrated
52
53 Research Center in Oncology: ONCOLille axe 1: resistance to loco-regional treatments”,
54
55 labelled by the French National Cancer Institute (INCa).
56
57
58
59
60

1
2
3 On a national level, Professor Mariette's innate dynamism and enthusiasm was the
4
5 origin of the creation of the French EsoGastric Tumours (FREGAT) clinical network,
6
7 promoting research in eso-gastric cancer in France since 2011. This network, associated with
8
9 the FREGAT clinico-biological database*, was funded by the French National Cancer
10
11 Institute (INCa) in 2013 and opened in January 2015. It combines as of today 46 clinical
12
13 teams from 33 hospitals in France. The FREGAT under his continuous leadership became one
14
15 of the most successful esophago-gastric project groups worldwide and has been
16
17 internationally admired for its amazing productivity and scientific excellence. Professor
18
19 Mariette was also a member of the French University National Council (CNU section 52.02)
20
21 since 2012 and became its Chairman in 2014. Since 2013 he was Chairman of the French
22
23 Federation of Surgical Research (FRENCH), in charge of the design of surgical national
24
25 clinical trials and the teaching of clinical research methodology. In addition, Professor
26
27 Mariette was a Member of the administrative council and Scientific Committee of the French
28
29 Federation of Digestive Oncology (FFCD - PRODIGE), coordinating several clinical trials
30
31 and encouraging multidisciplinary collaboration between surgeons, oncologists and related
32
33 specialties.
34
35
36
37

38 On an international scale, Professor Mariette was a member of several prestigious
39
40 scientific societies, including the European Surgical Association (ESA), the European Society
41
42 for Diseases of the Esophagus (ESDE, executive board member and treasurer since 2013) and
43
44 the International Society for Diseases of the Esophagus (ISDE). He participated in the
45
46 Editorial Board of several journals including the Annals of Surgery, Gastric Cancer, European
47
48 Journal of Surgical Oncology and Journal of Visceral Surgery. As a well-known international
49
50 expert in the field of the medical and surgical treatment in esophageal and gastric cancer, he
51
52 was regularly invited for conferences and educational courses in France and abroad.
53
54
55
56
57
58
59
60

1
2
3 Christophe was a pioneer and a leading person in esophageal surgery. We admire his
4
5 scientific productivity and how he challenged us to innovate and to think about the optimal
6
7 treatment for our patients. But beyond that he was a phenomenal surgeon with remarkable
8
9 technical skills and courage, someone to whom we all looked up and learned from. He
10
11 inspired us all with his intelligence, ethics, originality, extraordinary scientific skills and
12
13 ambition to bring upper gastro-intestinal surgery to a higher level.
14
15

16 Our thoughts go to his sister and brother to whom we extend our sincere condolences.
17
18 Christophe is now in the sky with the shooting stars.
19
20

21
22
23 *<https://www.fregat-database.org/>
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Disease



is Proof

MARIETTE Christophe



Current position

- Professor of surgery – MD, PhD Lille University Hospital, France
- Head of the department of digestive and oncological surgery
- Scientific fields of interest:
 - Oeso-gastric cancer multidisciplinary approach from basic science to the bed side - Main investigator or involved in several phase I to phase III clinical trials, basic and translational research programs
 - Cancer medical and surgical research
- Index H : 31
- Medical association number : 59/ 16 680

Identity and Contact

- Born 16/11/1969 Montreuil sous bois (93) FRANCE
- Nationality FRENCH
- Professional address : Dpt of digestive and oncological surgery, University Hospital Claude Huriez, Place de Verdun 59037 LILLE Cedex FRANCE

Biography

Civil Solidarity Pact since 2010 – 2 children

Scientific and Academic Degrees

2012: Head of Surgical Department
2006: University Professor – Senior Surgical Physician
2004: Accreditation to Supervise Research (HDR), Lille II University, France
2004: PhD Thesis in Life and Health Sciences, Inserm Unit U837, Lille, France
2001: Master Degree 2 in Surgical Sciences
2000: Specialised Digestive Surgery Certificate
1999: General Surgery Certificate
1999: MD Thesis, University of Lille II, France
1996: Master Degree 1 in biological sciences

Academic and scientific career

2014- : President of the University National Council (CNU section 52.02)
2012 -: Member of the University National Council (CNU section 52.02)
2012 -: Coordinator “Integrated Research Center in Oncology: ONCOLille “ axe 1: resistance to loco-regional treatments, labelled by the French NCI
2011 -: National coordinator of the French oeso-gastric working group (FREGAT) promoting research in oeso-gastric cancers.

2010- In charge of the cancer medical and scientific organisation in the Lille University Hospital and C2RC
2006 -

- Professor of Surgery, Dpt of digestive and oncological surgery, University Hospital of Lille, France
- Head of the Clinical Research Department, University Hospital of Lille, France
- Head of the Experimental Research Unit – oesophageal carcinogenesis section- National Institute of Health and Medical Research (INSERM) Unit 837, Lille, France

2008: ICH Good Clinical practice for clinical trial sites

2001-2006: Complementary diplomas in Medical Research Methodology; Medical pedagogy; Animal experimentation; Oncological surgery; Clinical research and biostatistics; Hepato-biliary surgery; Laparoscopic surgery; Master Degree 1 in medicine.

2001: Senior Surgical Physician

1999: Senior Hospital Lecturer in surgery

1994: Junior Surgical Resident

Editorial board, scientific societies and expert

▪ Editorial board

Editorial board member of Annals of Surgery (IF 8.3, rank 1 Surgery), Gastric Cancer (IF 3.0), European Journal of Surgical Oncology (IF 3.0), Journal of Visceral Surgery (IF 1.8)

▪ Scientific societies

2013- President of the French Federation of Surgical Research (FRENCH)

2013-Treasurer of the European Society for Diseases of the Esophagus (ESDE)

2009-2013: General secretary of the French Federation of Surgical Research (FRENCH) – In charge of the design of national clinical trials and clinical research methodology teaching.

2006-2010: Scientific president of the French Society of Digestive Surgery (SFCD)– In charge of producing national recommendations in surgery with the Health ministry (HAS) and of the SFCD-ACHBT national congress.

2009 -

- Member of the Clinical Research Committee of The National Cancer Institute (INCa)
- Member of the International Committee of Clinical Research in Oncology of The National Cancer Institute (INCa)
- Member of the EORTC scientific board
- Teacher in Medical Research Methodology and French Surgical Sciences Master

2006 –

Member of the administrative council and scientific committee of the French Federation of Digestive Oncology (FFCD - PRODIGE)

Member of the European Surgical Association (ESA)

Member of the scientific committee of the National Society of Gastroenterology (SNFGE)

Member of the European Society for Disease of the Esophagus (ESDE) and the International Society (ISDE)

Member of the administrative council and scientific committee of the French Association for Ambulatory Surgery (AFCA)

▪ Expert

- Well-known international expert in the field of the medical and surgical approaches in oesophageal and gastric cancers. Numerous invited conferences in EORTC, ASCO, ESMO-ECCO, UEGW and various European scientific societies (AUGIS, ERAS, ICACT.....)
- International reviewer for clinical trial grants dealing with oeso-gastric pathologies for the Health Ministries

of Germany, Ireland, UK, The Netherlands, Switzerland, Canada, Belgium, Czech Republic ...

- Reviewer for The Lancet, The Lancet Oncology, Annals of Surgery, Annals of Oncology, British Journal of Surgery, British Journal of Cancer, Annals of Surgical Oncology, European Journal of Cancer, Clinical Nutrition, European Journal of Clinical Nutrition, Digestive Surgery, Digestive Liver Diseases, Future Oncology, Journal of Surgical Oncology, Diseases of the Esophagus, European Journal of Surgical Oncology, BMC Gastroenterology, Journal of Visceral Surgery, Journal of Thoracic Surgery, Bulletin du cancer

Awards and Grants

▪ Awards:

- 1st place National Ranking of the best national upper GI surgical department since 2010 (Le Point and Capital magazines)
- Best scientific work 2011 by the National Cancer Institute and the French Surgical Academy about: "The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study" published in Annals of Surgery Nov 2011.
- PhD Thesis Certification – First Place - 2006
- 18 times elected as best oral communications in national or international congresses

▪ Grants:

- 2016: : Public contract (PHRC National Cancer Institute) for French participation to phase III international study (167 k€)
- 2016 : Public Contract (Ligue Contre le Cancer) for a pilot study on gastric signet ring cell (34 k€)
- 2015: Public contract (Nord Pas de Calais Region) for phase III international collaborative translational study (100 k€)
- 2015: Public contract (PHRC National Cancer Institute) for phase III national clinical study (852 314 euros)
- 2014: Public contract (PHRC National Cancer Institute) for phase III national clinical study (co-coord 268 000 euros)
- 2013: Public contract (PHRC National Cancer Institute) for phase III national clinical study (co-coord 463 000 euros)
- 2013: Fondation de l'Avenir contract for basic science activities (23 000 for 1 year)
- 2012: SIRIC ONCOLILLE, Comprehensive cancer center, French NCI labelled. Scientific program Director. (6,7 M euros)
- 2012: Public contract (French NCI support) for a national oesogastric cancer database construction (709 416 euros)
- 2011: Public contract (STIC National program) for phase III national clinical study (600 000 euros)
- 2011: Public contract (PHRC National Cancer Institute) for phase III national clinical study (425 000 euros)
- 2009: Medical Research Foundation (FRM) label for basic science activities (300 000 euros for 3 years)
- 2009: Private contract (Merck Oncology lab.) for phase II national clinical study (300 000 euros)
- 2008: Public contract (PHRC National Cancer Institute) for phase III national clinical study (300 000 euros)
- 2007: Fondation de l'Avenir contract for basic science (30 000 for 1 year)
- 2006 : Ligue contre le Cancer Contract for basic science activities (19500 euros)
- 2006 : Public contract (PHRC National Cancer Institute) for phase III national clinical study (100 000 euros)
- 2001 : Ligue contre le Cancer contract for basic science activities (30490 euros)
- 2000 : Association de Recherche contre le Cancer (ARC) for basic science activities (45734 euros)

• Supervision of students :

- 7 international fellows
- 4 PhD thesis
- 32 MD thesis
- 12 Master Degree

Selected Publications 2008-2017

- Mantziari S, Gronnier C, Renaud F, Duhamel A, Théreaux J, Brigand C, Carrère N, Lefevre JH, Pasquer A, Demartines N, Collet D, Meunier B, Mariette C; FREGAT working group – FRENCH – AFC. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study. **Ann Surg.** 2017 Nov;266(5):805-813.

- Degisors S, Pasquer A, Renaud F, Béhal H, Hec F, Gandon A, Vanderbeken M, Caranhac G, Duhamel A, Piessen G, [Marianne C](#); FREGAT working group. Are Thoracotomy and/or Intrathoracic Anastomosis Still Predictors of Postoperative Mortality After Esophageal Cancer Surgery?: A Nationwide Study. *Ann Surg.* 2017 Nov;266(5):854-862. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction
- Duhamel A, Labreuche J, Gronnier C, [Marianne C](#). Statistical Tools for Propensity Score Matching. *Ann Surg.* 2017 Jun;265(6):E79-E80.
- Markar SR, Gronnier C, Pasquer A, Duhamel A, Behal H, Théreaux J, Gagnière J, Lebreton G, Brigand C, Meunier B, Collet D, [Marianne C](#); FREGAT working group – FRENCH – AFC. Surgically treated oesophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes. *Eur J Cancer.* 2017 Apr;75:179-189. doi: 10.1016/j.ejca.2016.12.036. Epub 2017 Feb 23.
- Piessen G, Lefèvre JH, Cabau M, Duhamel A, Behal H, Perniceni T, Mabrut JY, Regimbeau JM, Bonvalot S, Tiberio GA, Mathonnet M, Regenet N, Guillaud A, Glehen O, Mariani P, Denost Q, Maggiori L, Benhaim L, Manceau G, Mutter D, Bail JP, Meunier B, Porcheron J, [Marianne C](#), Brigand C; AFC and the FREGAT working group. Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors: What Is the Impact on Postoperative Outcome and Oncologic Results? *Ann Surg.* 2015 Nov;262(5):831-40
- Pasquer A, Renaud F, Hec F, Gandon A, Vanderbeken M, Drubay V, Caranhac G, Piessen G, [Marianne C](#); FREGAT Working Group FRENCH. Is Centralization Needed for Esophageal and Gastric Cancer Patients With Low Operative Risk?: A Nationwide Study. *Ann Surg.* 2016 Nov;264(5):823-830.
- Gandon A, Gronnier C, Renaud F, Borde P, Vanderbeken M, Hec F, Piessen G, Adenis A, Mirabel X, [Marianne C](#).
- Esophageal Adenocarcinoma: Impact of a Large Hiatal Hernia on Outcomes After Surgery. *Ann Surg.* 2016 Nov;264(5):862-870.
- Pasquer A, Renaud F, Hec F, Gandon A, Vanderbeken M, Drubay V, Caranhac G, Piessen G, [Marianne C](#); FREGAT Working Group FRENCH. Is Centralization Needed for Esophageal and Gastric Cancer Patients With Low Operative Risk?: A Nationwide Study. *Ann Surg.* 2016 Nov;264(5):823-830.
- Gandon A, Gronnier C, Renaud F, Borde P, Vanderbeken M, Hec F, Piessen G, Adenis A, Mirabel X, [Marianne C](#). Esophageal Adenocarcinoma: Impact of a Large Hiatal Hernia on Outcomes After Surgery. *Ann Surg.* 2016 Nov;264(5):862-870.
- Messenger M, Pasquer A, Duhamel A, Caranhac G, Piessen G, [Marianne C](#); FREGAT working group FRENCH. Laparoscopic Gastric Mobilization Reduces Postoperative Mortality After Esophageal Cancer Surgery: A French Nationwide Study. *Ann Surg.* 2015 Nov;262(5):817-23.
- Robb WB, Messenger M, Dahan L, Mornex F, Maillard E, D'Journo XB, Triboulet JP, Bedenne L, Seitz JF, [Marianne C](#); Fédération Francophone de Cancérologie Digestive, Société Française de Radiothérapie Oncologique, Union des Centres de Lutte Contre le Cancer, Groupe Coopérateur Multidisciplinaire en Oncologie and the French EsoGastric Tumour working group - Fédération de Recherche En Chirurgie. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. *Br J Surg.* 2015 Oct 29.
- Markar S, Gronnier C, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Brigand C, Vaillant JC, Adham M, Msika S, Demartines N, Nakadi IE, Meunier B, Collet D, [Marianne C](#); FREGAT (French Eso-Gastric Tumors) working group, FRENCH (Fédération de Recherche EN Chirurgie), and AFC (Association Française de Chirurgie). The Impact of Severe Anastomotic Leak on Long-term Survival and Cancer Recurrence After Surgical Resection for Esophageal Malignancy. *Ann Surg.* 2015 Dec;262(6):972-80.
- Vacchelli E, Semeraro M, Enot DP, Chaba K, Poirier Colame V, Dartigues P, Perier A, Villa I, Rusakiewicz S, Gronnier C, Goéré D, [Marianne C](#), Zitvogel L, Kroemer G. Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. *Oncotarget.* 2015 Aug 28;6(25):20840-50.
- [Marianne C](#), Robb WB, Piessen G, Adenis A. Neoadjuvant chemoradiation in oesophageal cancer. *Lancet Oncol.* 2015 Sep;16(9):1008-9.
- Markar S, Gronnier C, Duhamel A, Pasquer A, Théreaux J, du Rieu MC, Lefevre JH, Turner K, Luc G, [Marianne C](#). Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option? *J Clin Oncol.* 2015 Nov 20;33(33):3866-73
- Markar SR, Gronnier C, Duhamel A, Pasquer A, Théreaux J, du Rieu MC, Lefevre JH, Turner K, Luc G, [Marianne C](#); FREGAT Working Group-FRENCH-AFC. Significance of Microscopically Incomplete Resection Margin After Esophagectomy for Esophageal Cancer. *Ann Surg.* 2015 Jul 1.
- Gronnier C, Tréchet B, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Brigand C, Vaillant JC, Adham M, Msika S,

- Demartines N, El Nakadi I, Piessen G, Meunier B, Collet D, [Mariette C](#); On behalf of the FREGAT Working Group-FRENCH-AFC. Impact of Neoadjuvant Chemoradiotherapy on Postoperative Outcomes After Esophageal Cancer Resection: Results of a European Multicenter Study. *Ann Surg*. 2014;260:764-771.
- Robb WB, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Brun-Ly VL, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF, [Mariette C](#); the Fédération Française de Cancérologie Digestive, Société Française de Radiothérapie Oncologique, Union des Centres de Lutte Contre le Cancer, Groupe Coopérateur Multidisciplinaire en Oncologie, French EsoGAstic Tumour working group, Fédération de Recherche En Chirurgie. Impact of Neoadjuvant Chemoradiation on Lymph Node Status in Esophageal Cancer: Post hoc Analysis of a Randomized Controlled Trial. *Ann Surg*. 2015 May;261(5):902-8.
 - Robb WB, Bruyere E, Amielh D, Vinatier E, Mabrut JY, Perniceni T, Piessen G, [Mariette C](#); on-behalf-of the FREGAT Working Group-FRENCH. Esophageal Gastrointestinal Stromal Tumor: Is Tumoral Enucleation a Viable Therapeutic Option? *Ann Surg*. 2015 Jan;261(1):117-24.
 - Mortensen K, Nilsson M, Slim K, Schäfer M, [Mariette C](#), Braga M, Carli F, Demartines N, Griffin SM, Lassen K; Enhanced Recovery After Surgery (ERAS®) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. *Br J Surg*. 2014;101:1209-29.
 - [Mariette C](#), Dahan L, Maillard E et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCO 9901. *J Clin Oncol*. 2014;32:2416-22.
 - Lahdaoui F, Delpu Y, Vincent A, Renaud F, Messenger M, Duchêne B, Leteurtre E, [Mariette C](#), Torrisani J, Jonckheere N, Van Seuning I. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. *Oncogene*. 2014;0:1-9.
 - Stahl M, [Mariette C](#), Haustermans K, Cervantes A, Arnold D; ESMO Guidelines Working Group. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013 Oct;24 Suppl 6:vi51-6.
 - Piessen G, Messenger M, Mirabel X, Briez N, Robb WB, Adenis A, [Mariette C](#). Is there a role for surgery for patients with a clinical complete response after chemoradiation for esophageal cancer? *Ann Surg* 2013;258:793-9
 - Piessen G, Messenger M, Robb W, Bonnetain F, [Mariette C](#). Gastric signet ring cell carcinoma: how to investigate its impact on survival. *J Clin Oncol*. 2013 Apr 22
 - Gronnier C, Messenger M, Robb W, Thiebot T, Louis D, Luc G, Piessen G, [Mariette C](#). On behalf of the FREGAT Working Group – FRENCH. Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma? *Surgery* 2013;154:955-67.
 - Robb W, Messenger M, Goere D, Pichot-Delahaye V, Lefevre JF, Louis D, Guiramand J, Kraft K, [Mariette C](#) On behalf of the FREGAT Working Group – FRENCH. *JAMA Surg*. 2013;20:1-8.
 - Piessen G, Petyt G, Duhamal A, Mirabel X, Huglo D, [Mariette C](#). Ineffectiveness of 18-Fluorodeoxyglucose Positron Emission Tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. *Ann Surg*. 2013;258:793-9.
 - Briez N, Piessen G, Torres F, Lebuffe G, Triboulet JP, [Mariette C](#). Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. *Br J Surg*. 2012;99:1547-53.
 - [Mariette C](#), Robb WB. Minimally invasive versus open oesophagectomy for oesophageal cancer. *Lancet*. 2012;380(9845):883.
 - Lutz MP, Zalberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, [Mariette C](#), Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F; First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. *Eur J Cancer*. 2012;48:2941-53.
 - Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA*. 2012;308:147-56.
 - Messenger M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, [Mariette C](#); FREGAT working group - FRENCH. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. *Ann Surg*. 2011;254:684-93.

- Pessaux P, Sauvanet A, [Mariette C](#), Paye F, Muscari F, Cunha AS, Sastre B, Arnaud JP; Fédération de Recherche en Chirurgie (French). External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial. *Ann Surg.* 2011;253:879-85.
- [Mariette C](#), Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which therapeutic approach? *Lancet Oncol.* 2011;12:296-305.
- Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, [Mariette C](#), Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA.* 2010;304:1073-81.
- Piessen G, Messenger M, Leteurtre E, Jean-Pierre T, [Mariette C](#). Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. *Ann Surg.* 2009;250:878-87.
- Chauffert B, Mornex F, Bonnetain F, Rougier P, [Mariette C](#), Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremmsdoerfer N, Maingon P, Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. *Ann Oncol.* 2008;19:1592-9.
- [Mariette C](#), Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. *Ann Surg.* 2008;247:365-71.
- Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, [Mariette C](#), Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. *Immunol Rev.* 2007;220:47-59. Review.
- [Mariette C](#), Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. *Lancet Oncol.* 2008;8:545-53. Review.